ArticlePloS one2018
The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06071195 (All-in-One Prostate Cancer Staging with MRI), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
All-in-One Prostate Cancer Staging with MRI
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis.The oncologist · 2023Pooled it
- Evaluation of audiovisual and auditory interventions on exam anxiety during whole-body magnetic resonance imaging in cancer patients: a quasi-experimental study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Observational
- Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.NPJ breast cancer · 2026Article
- Automated Field of View Prescription for Whole-body Magnetic Resonance Imaging Using Deep Learning Based Body Region Segmentations.Investigative radiology · 2025Article
- Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology.Breast (Edinburgh, Scotland) · 2024Article
- Reporting on invasive lobular breast cancer in clinical trials: a systematic review.NPJ breast cancer · 2024Review
- Deep Learning for Delineation of the Spinal Canal in Whole-Body Diffusion-Weighted Imaging: Normalising Inter- and Intra-Patient Intensity Signal in Multi-Centre Datasets.Bioengineering (Basel, Switzerland) · 2024Article
- Whole-Body MRI in Musculoskeletal Oncology: A Comprehensive Review with Recommendations.Radiology. Imaging cancer · 2023Review
- Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.Therapeutic advances in medical oncology · 2023Review
- Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study.Diagnostics (Basel, Switzerland) · 2021Article
- Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements.Diagnostics (Basel, Switzerland) · 2021Article
- Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography.Frontiers in oncology · 2021Review
- Whole-body magnetic resonance imaging: technique, guidelines and key applications.Ecancermedicalscience · 2021Review
- What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century.The British journal of radiology · 2020Review
- Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Review
- Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses.La Radiologia medica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the impact of whole-body MRI (WB-MRI) in addition to CT of chest-abdomen-pelvis (CT-CAP) and 18F-FDG PET/CT (PET/CT) on systemic treatment decisions in standard clinical practice for patients with advanced breast cancer (ABC). WB-MRI examinations in ABC patients were extracted from our WB-MRI registry (2009-2017). Patients under systemic treatment who underwent WB-MRI and a control examination (CT-CAP or PET/CT) were included. Data regarding progressive disease (PD) reported either on WB-MRI or on the control examinations were collected. Data regarding eventual change in treatment after the imaging evaluation were collected. It was finally evaluated whether the detection of PD by any of the two modalities had induced a change in treatment. Among 910 WB-MRI examinations in ABC patients, 58 had a paired control examination (16 CT-CAP and 42 PET/CT) and were analysed. In 23/58 paired examinations, additional sites of disease were reported only on WB-MRI and not on the control examination. In 17/28 paired examinations, PD was reported only on WB-MRI and not on the control examination. In 14 out of the 28 pairs of examinations that were followed by a change in treatment, PD had been reported only on WBMRI (14/28; 50%), while stable disease had been reported on the control examination. In conclusion, WB-MRI disclosed PD earlier than the control examination (CT-CAP or PET/CT), and it was responsible alone for 50% of all changes in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.